In this regard, interesting data emerged from the Empower-Lung 1 study, in which the costs of cemiplimab in first-line treatment of NSCLC patients with at least 50% PD-L1 expression were compared to those in patients treated with chemotherapy, showing that cemiplimab was a cost-effective option [57]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.